Chemotherapy-associated thrombocytopenia current and emerging management strategies

American Journal of Cancer

Volumn 5, Issue 6, 2006, Pages 371-382

  Jelic, Svetislav ^a   Radulovic, Sinisa ^a  

^a INSTITUTE FOR ONCOLOGY AND RADIOLOGY OF SERBIA   (Serbia)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; CYTOTOXIC AGENT; DACTINOMYCIN; ELTROMBOPAG; FLUDARABINE; GEMCITABINE; HEPARIN; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 3; INTERLEUKIN 6; LEUKEMIA INHIBITORY FACTOR; MITOMYCIN; OXALIPLATIN; PEGACARISTIM; PLATINUM COMPLEX; PROMEGAPOIETIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 11; RITUXIMAB; STEM CELL FACTOR; THROMBOCYTE ANTIBODY; THROMBOPOIETIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ALLOIMMUNIZATION; ANEMIA; AUTOIMMUNE THROMBOCYTOPENIA; B CELL LYMPHOMA; BACTERIUM CONTAMINATION; BLEEDING; BLOOD DYSCRASIA; BLOOD TRANSFUSION REACTION; BONE MARROW APLASIA; BONE MARROW CANCER; BONE MARROW DEPRESSION; BONE MARROW HYPOPLASIA; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DIFFERENTIAL DIAGNOSIS; DISEASE EXACERBATION; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; EMBOLISM; ERYTHROCYTE LIFESPAN; FOLLICULAR LYMPHOMA; GRAM NEGATIVE INFECTION; GRANULOCYTOPENIA; HEALTH CARE ORGANIZATION; HEMOGLOBIN BLOOD LEVEL; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HEPATITIS B; HEPATITIS C; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IDIOPATHIC THROMBOCYTOPENIC PURPURA LIKE SYNDROME; IMMUNOPATHOLOGY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LUNG SARCOMA; METASTASIS; MYASTHENIA GRAVIS; PARASITE TRANSMISSION; PLASMA TRANSFUSION; PRIORITY JOURNAL; REVIEW; RHABDOMYOSARCOMA; RISK ASSESSMENT; RISK FACTOR; SEPSIS; SIDE EFFECT; SYNDROME; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOCYTOPOIESIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME;

EID: 33846888264     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605060-00004     Document Type: Review

References (110)

1. National Cancer Institute. Cancer therapy evaluation program: common toxicity criteria manual, version 2.0. Bethesda (MD): NCI, 1999
2. Guest I, Uetrecht J. Bone marrow stem cell protection from chemotherapy by low-molecular-weight compounds. Exp Hematol 2001; 29 (2): 123-37
3. Catino A, Crucitta E, Latorre A, et al. Amifostine as chemoprotectant in metastatic breast cancer patients treated with doxorubicin. Oncol Rep 2003; 10 (1): 163-7
4. Lorusso D, Ferrandina G, Greggi S, et al. Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 2003; 14 (7): 1086-93
5. Spath-Schwalbe E, Lange C, Genvresse I, et al. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma: a phase II study. Anticancer Drugs 2002; 13 (4): 395-403
6. Dourakis SP, Deutsch M, Hadziyannis SJ. Immune thrombocytopenia and alphacytopenia interferon therapy. J Hepatol 1996; 25 (6): 972-5
7. Fujii H, Kitada T, Yamada T, et al. Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C. Hepatogastroenterology 2003; 50 (51): 841-2
8. Peck-Radosavljevic M, Wichlas M, Pidlich J, et al. Blunted thrombopoietin response to interferon alpha-induced thrombocytopenia during treatment for hepatitis C. Hepatology 1998; 28 (5): 1424-9
9. Sagir A, Wettstein M, Heintges T, et al. Autoimmune thrombocytopenia induced by PEG-INFα2b plus ribavirin in hepatitis C. Digest Dis Sci 2002; 47 (3): 562-3
10. George MM, Li SD, Mindikoglu AL, et al. Platelet sparing effect of COX II inhibition used with pegylated interferon alpha-2a for the treatment of chronic hepatitis C: a short term pilot study. Cytokine 2004; 27 (6): 159-65
11. Peck-Radosavljevic M, Wichlas M, Homoncik-Kraml M, et al. Rapid suppression of hematopoiesis by standard or pegylated interferon-alpha. Gastroenterology 2002; 123 (1): 141-51
12. Sata M, Yano Y, Yoshiyama Y, et al. Mechanisms of thrombocytopenia induced by interferon therapy for chronic hepatitis B. J Gastroenterol 1997; 32 (2): 206-10
13. Telek B, Batar P, Uvardy M. Successful combined treatment with rituximab and high dose immunoglobulin in a patient with chronic lymphocytic leukemia with fludarabine-induced severe immune thrombocytopenia. Orv Hetil 2005; 146 (34): 1791-3
14. Hegde UP, Wilson WH, White T, et al. Rituximab treatment of refractory fludarabine-associated immune thrombocytopenia in chronic lymphocytic leukemia. Blood 2002; 100 (6): 2260-2
15. Usman M, Adil SN, Sajid R, et al. Fludarabine induced immune thrombocytopenia in a patients with CD5 positive B cell chronic lymphocytic leukemia. Eur J Haematol 2004; 73 (4): 251-7
16. Fernandez MJ, Llopis I, Pastor E, et al. Immune thrombocytopenia induced by fludarabine successfully treated with rituximab. Haematologica 2003; 88 (2): ELT02
17. Fujimaki K, Takasaki H, Koharazawa H, et al. Idiopathic thrombocytopenic purpura and myasthenia gravis after fludarabine treatment for chronic lymphocytic leukemia. Leuk Lymphoma 2005; 46 (7): 1101-2
18. Leo E, Scheuer L, Schmidt-Wolf IG, et al. Significant thrombocytopenia associated with the addition of rituximab to a combination of fludarabine and cyclophosphamide in the treatment of relapsed follicular lymphoma. Eur J Haematol 2004; 73 (4): 251-7
19. Koutras A, Makatsoris T, Paliogianni F, et al. Oxaliplatin-induced acute-onset thrombocytopenia, hemorrhage and hemolysis. Oncology 2004; 67 (2): 179-82
20. Khatua S, Nair CN, Ghosh K. Immune-mediated thrombocytopenia following dactinomycin therapy in a child with alveolar rhabdomyosarcoma: the unresolved issues. J Pediatr Hematol Oncol 2004; 26 (11): 777-9
21. Arimura K, Arima N, Ohtsubo H, et al. Severe autoimmune thrombocytopenic purpura during interferon-alpha therapy for chronic myelogenous leukemia. Acta Haematol. 2004; 112 (4): 217-8
22. Gundappa RK, Sud K, Kohli HS, et al. Mitomycin-C induced hemolytic uremic syndrome: a case report. Ren Fail 2002; 24 (3): 373-7
23. Duvic C, Sarret D, Coutant G, et al. Hemolytic-uremic syndrome caused by mitomycin c: long-term management. Ann Med Interne (Paris) 2000; 151 (1): 70-3
24. Lesesne JB, Rothschild N, Erickson B, et al. PV, Cancer-associated hemolytic-uremic syndrome: analysis of 85 cases from a national registry. J Clin Oncol 1989; 7 (12): 781-9
25. Porta C, Caporali R, Montecucco C. Autoimmunity in thrombotic thrombocytopenic purpura. Semin Thromb Hemost 2005; 31 (6): 633-40
26. Medina PJ, Sipols JM, George JN. Drug-associated thrombotic thrombocytopenic purpura-hemolytic uremic syndrome. Curr Opin Hematol 2001; 8 (5): 286-93
27. Al Aly Z, Philoctete Ashley JM, Gellens ME, et al. Thrombotic thrombocytopenic purpura in a patient treated with imatinib mesylate: true association or mere coincidence? Am J Kidney Dis 2005; 45 (4): 762-8
28. Muller S, Schutt P, Bojko P, et al. Hemolytic uremic syndrome following prolonged gemcitabine therapy: report of four cases from a single institution. Ann Hematol 2005; 84 (2): 110-4
29. Lewin SN, Mutch DG, Whitcomb BP, et al. Three cases of hemolytic uremic syndrome in ovarian cancer patients treated with combination gemcitabine and pegylated liposomal doxorubicin. Gynecol Oncol 2005; 97 (1): 228-33
30. Venat-Bouvet L, Ly K, Szelag JC, et al. Thrombotic microangiopathy and digital necrosis: two unrecognized toxicities of gemcitabine. Anticancer Drugs 2003; 14 (10): 829-32
31. Teixeira L, Debourdeau P, Zammit C, et al. Gemcitabine-induced thrombotic microangiopathy. Presse Med 2002; 31 (16): 740-2
32. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine-associated thrombotic microangiopathy. Cancer 2004; 100 (12): 2664-70
33. Rapoport BL, Falkson G, Alberts AS, et al. "Idiopathic thrombocytopenic purpura-like syndrome" treated with interferon in a patient with lung cancer. Am J Hematol 1990; 34 (1): 71-2
34. Tsoussis S, Ekonomidou F, Vourliotaki E, et al. Successful treatment of idiopathic thrombocytopenic purpura-like syndrome in a cancer patient with low-dose interferon: case report and review of the literature. Am J Hematol 2004; 76 (4): 353-9
35. Kinasewitz GT, Zein JG, Lee GL, et al. Prognostic value of a simple evolving disseminated intravascular coagulation score in patients with severe sepsis. Crit Care Med 2005; 33 (10): 2214-21
36. Sivula M, Tallgren M, Pettila V. Modified score for disseminated intravascular coagulation in the critically ill. Intensive Care Med 2005; 31 (9): 1209-14
37. Jelic S, Bojic P, Rosic D. Microangiopathic hemolytic anemia with erythroblastosis in a patient with disseminated pancreatic carcinoma and leptospirosis. Srp Arh Celok Lek 1997; 105 (10): 855-65
38. Aird WC. The hematologic system as a marker of organ dysfunction in sepsis. Mayo Clin Proc 2003; 78 (7): 869-81
39. Khashu M, Osiovich H, Henry D, et al. Persistent bacteremia and severe thrombocytopenia caused by coagulase-negative Staphylococcus in a neonatal intensive care unit. Pediatrics 2006; 117 (2): 340-8
40. Laber DA, Martin ME. Etiology of thrombocytopenia in all patients treated with heparin products. Eur J Haematol 2005; 75 (2): 101-5
41. Christie DJ, van Buren N, Lennon SS, et al. Vancomycin-dependent antibodies associated with thrombocytopenia and refractoriness to platelet transfusion inpatients with leukemia. Blood 1990; 75 (2): 518-23
42. Ishiguro H, Fung MC, Inoue Y, et al. Evidence-based management of chemotherapy related thrombocytopenia. Gan To Kagaku Ryoho 2003; 30 (12): 2001-7
43. Shyder E, Mechanig SA. Bone marrow dysfunction in the cancer patients. In: DeVita VT, Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. Philadelphia (PA): Lippincott-Raven, 1997: 2607-20
44. Rebulla P, Finazzi G, Marangoni F, et al. The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia: Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. N Engl J Med 1997; 337 (26): 1870-5
45. Yoshiko T, Hideki T, Rieko N, et al. Good correlation between clinical bleeding tendencies and bleeding pattern from the bleeding time incision. Thromb Res 1999; 95: 131-4
46. Klein H, editor. Standards for blood banks and transfusion services. 17th ed. Bethesda (MD): American Association of Blood Banks, 1996
47. Slichter S. Principles of platelet transfusion therapy. In: Hoffman R, Benz EJ, Shattil SJ, et al., editors. Hematology: basic principles and practice. 2nd ed. New York: Churchill Livingstone, 1995: 1987
48. Yankee RA, Grument FC, Rogentine GN. Platelet transfusion therapy: the selection of compatible platelet donors for refractory patients by lymphocyte HLA typing. N Engl J Med 1969; 281: 1208-12
49. Simonsen AC, Johansson PI, Conlan MG, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006; 46 (3): 424-33
50. Saarinen UM, Kekomaki R, Siimes M, et al. Effective prophylaxis against platelet refractoriness in multitransfused patients by use of leukocyte-free blood components. Blood 1990; 75: 512-7
51. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions: the Trial to Reduce Alloimmunization to Platelets Study Group. N Engl J Med 1997; 337 (26): 1861-9
52. KickIer T, Braine HG, Piantadosi S, et al. A randomized placebo-controlled trial intravenous gammaglobulin in aIloimmunized thrombocytopenic patients. Blood 1990; 75: 313-6
53. Lee EJ, Norris D, Schiffer CA. Intravenous immune globulin for patients alloimmunized to random donor platelet transfusion. Transfusion 1987; 27: 245-7
54. Lee EJ, Schiffer CA. Serial measurement of lymphocytotoxic antibody and response to nonmatched platelet transfusions in alloimmunized patients. Blood 1987; 70: 1727-9
55. Duquesnoy RJ, Anderson AJ, Tomasulo PA, et al. ABO compatibility and platelet transfusions of alloimmunized thrombocytopenic patients. Blood 1979; 54: 595
56. McLeod BC, Piehl MR, Sassetti RJ. Alloimmunization to RhD by platelet transfusions in autologous bone marrow transplant recipients. Vox Sang 1990; 59 (3): 185-9
57. Mollicone R, Caillard T, Le Pendu J, et al. Expression of ABH and X (Lex) antigens on platelets and lymphocytes. Blood 1988; 71 (4): 1113-9
58. Cooling LL, Kelly K, Barton J, et al. Determinants of ABH expression on human blood platelets. Blood 2005; 105 (8): 3356-64
59. Heal JM, Blumberg N. Optimizing platelet transfusion therapy. Blood Rev 2004; 18 (3): 149-65
60. Slichter SJ, Davis K, Enright H, et al. Factors affecting posttransfusion platelet increments, platelet refractoriness, and platelet transfusion intervals in thrombocytopenic patients. Blood 2005; 105 (10): 4106-14
61. Blajchman MA, Beckers EA, Dickmeiss E, et al. Bacterial detection of platelets: current problems and possible resolutions. Transfus Med Rev 2005; 19 (4): 259-72
62. Centers for Disease Control and Prevention (CDC). Fatal bacterial infections associated with platelet transfusions: United States, 2004. MMWR Morb Mortal Wkly Rep 2005; 54 (7): 168-70
63. Lee CK, Ho PL, Chan NK, et al. Impact of donor arm skin disinfection on the bacterial contamination rate of platelet concentrates. Vox Sang 2002; 83 (3): 204-8
64. Chang AH, Kirsch CM, Mobashery N, et al. Streptococcus bovis septic shock due to contaminated transfused platelets. Am J Hematol 2004; 77 (3): 282-6
65. Boyeldieu D, Vu-Thien H, Dollfus C, et al. Klebsiella oxytoca septicemia following platelet transfusion. Pathol Biol (Paris) 1999; 47 (5): 405-7
66. Golubic-Cepulic B, Budimir A, Plecko V, et al. Morganella morganii causing fatal sepsis in a platelet recipient and also isolated from a donor's stool. Transfus Med 2004; 14 (3): 237-40
67. Blajchman MA, Goldman M, Baeza F. Improving the bacteriological safety of platelet transfusions. Transfus Med Rev 2004; 18 (1): 11-24
68. Burns KH, Werch JB. Bacterial contamination of platelet units: a case report and literature survey with review of upcoming American Association of Blood Banks requirements. Arch Pathol Lab Med 2004; 128 (3): 279-81
69. Cohen BJ, Beard S, Knowles WA, et al. Chronic anemia due to parvovirus B19 infection in a bone marrow transplant patient after platelet transfusion. Transfusion 1997; 37 (9): 947-52
70. Przepiorka D, LeParc GF, Werch J, et al. Prevention of transfusion-associated cytomegalovirus infection: practice parameter. American Society of Clinical Pathologists. Am J Clin Pathol 1996; 106 (2): 163-9
71. Widell A, Elmud H, Persson MH, et al. Transmission of hepatitis C via both erythrocyte and platelet transfusions from a single donor in serological window-phase of hepatitis C. Vox Sang 1996; 71 (1): 55-7
72. Kopko PM, Fernando LP, Bonney EN, et al. HIV transmissions from a window-period platelet donation. Am J Clin Pathol 2001; 116 (4): 562-6
73. Ling AE, Robbins KE, Brown TM, et al. Failure of routine HIV-1 tests in a case involving transmission with preseroconversion blood components during the infectious window period. JAMA 2000; 284 (2): 210-4
74. Sandler SG, Yu H, Rassai N. Risks of blood transfusion and their prevention. Clin Adv Hematol Oncol 2003; 1 (5): 307-13
75. Dobroszycki J, Herwaldt BL, Boctor F, et al. A cluster of transfusion-associated babesiosis cases traced to a single asymptomatic donor. JAMA 1999; 281 (10): 927-30
76. Mathur P, Samantaray JC. The first probable case of platelet transfusion-transmittted visceral leishmaniasis. Transfus Med 2004; 14 (4): 319-21
77. Riccardi D, Raspollini E, Rebulla P, et al. Relationship of the time of storage and transfusion reactions to platelet concentrates from buffy coats. Transfusion 1997; 37 (5): 528-30
78. Domen RE, Hoeltge GA. Allergic transfusion reactions: an evaluation of 273 consecutive reactions. Arch Pathol Lab Med 2003; 127 (3): 316-20
79. Curtis BR, McFarland JG. Mechanisms of transfusion-related acute lung injury (TRALI): anti-leukocyte antibodies. Crit Care Med 2006; 34 (5 Suppl.): S118-23
80. Kimura H, Ishibashi T, Shikama Y, et al. Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6. Blood 1990; 76 (12): 2493-500
81. Metcalf D, Begley CG, Johnson GR, et al. Effects of purified bacterially synthsized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice. Blood 1986; 68 (1): 46-57
82. Leonardi V, Danova M, Fincato G, et al. Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia. Oncol Rep 1998; 5 (6): 1459-64
83. Gordon MS, McCaskill-Stevens WJ, Battiato LA, et al. A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy. Blood 1996; 87 (9): 3615-24
84. Cairo MS, Davenport V, Bessmertny O, et al. Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. Br J Haematol 2005; 128 (1): 49-58
85. Kaye JA. FDA licensure of NEUMEGA to prevent severe chemotherapy-induced thrombocytopenia. Stem Cells 1998; 16 Suppl. 2: 207-23
86. Farese AM, Smith WG, Giri JG, et al. Promegapoietin-1a, an engineered chimeric IL-3 and Mpl-L receptor agonist, stimulates hematopoietic recovery in conventional and abbreviated schedules following radiation-induced myelosuppression in nonhuman primates. Stem Cells 2001; 19 (4): 329-38
87. Underhill CR, Basser RL. Thrombopoietin: an update on therapeutic potential. Biodrugs 1999; 11 (4): 261-76
88. Chang MS, McNinch J, Basu R, et al. Cloning and characterization of the human megakaryocyte growth and development factor (MGDF) gene. J Biol Chem 1995; 270 (2): 511-4
89. Foster DC, Sprecher CA, Grant FJ, et al. Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization. Proc Natl Acad Sci U S A 1994; 91 (26): 13023-7
90. Geddis AE, Linden HM, Kaushansky K. Thrombopoietin: a pan-hematopoietic cytokine. Cytokine Growth Factor Rev 2002; 13 (1): 61-73
91. Kuter DJ, Begley CG. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies. Blood 2002; 100 (10): 3457-69
92. Vadhan-Raj S, Cohen V, Bueso-Ramos C. Thrombopoietic growth factors and cytokines. Curr Hematol Rep 2005; 4 (2): 137-44
93. Basser RL, Rasko JE, Clarke K, et al. Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer. Lancet 1996; 348 (9037): 1279-81
94. Crawford J, Glaspy J, Belani C, et al. A randomized placebo-controlled, blinded, dose-scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) with filgrastim support in non-small-cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy. Proc Am Soc Clin Oncol 1998; 17: 73
95. Vadhan-Raj S. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia. Semin Hematol 2000; 37 (2 Suppl. 4): 28-34
96. Archimbaud E, Ottmann OG, Yin JA, et al. A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia. Blood 1999; 94 (11): 3694-701
97. Schiffer CA, Miller K, Larson RA, et al. A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia. Blood 2000; 95 (8): 2530-5
98. Cripe L, Neuberg D, Tallman M, et al. A pilot study of recombinant human thrombopoietin (rhTPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AML). Blood 1998, 92: 616
99. Li J, Yang C, Xia Y, et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98 (12): 3241-8
100. Cwirla SE, Balasubramanian P, Duffin DJ, et al. Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine. Science 1997; 276 (5319): 1696-9
101. Kimura T, Kaburaki H, Miyamoto S, et al. Discovery of a novel thrombopoietin mimic agonist peptide. J Biochem (Tokyo) 1997; 122 (5): 1046-51
102. Kaushansky K. Hematopoietic growth factor mimetics. Ann N Y Acad Sci 2001; 938: 131-8
103. Broudy VC, Lin NL. AMG531 stimulates megakaryopoiesis in vitro by binding to Mpl. Cytokine 2004; 25: 52-60
104. Tong W, Lodish HF. Lnk inhibits TPO-MPL signaling and TPO-mediated megakaryocytipoiesis. J Exp Med 2004; 200: 569-80
105. Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 31, a novel thrombopoietin receptor ligand. Clin Pharmacol Ther 2004; 76 (6): 628-38
106. Erickson-Miller C, Delome E, Tian S-S, et al. In vitro biological activity of SB-497115, an orally bioavailable, small molecule platelet growth factor. Eur J Cancer 2005; Suppl. 3 (2): 49
107. Jenkins J, Williams D, Collins DA, et al. SB-497115, a novel, oral platelet growth factor, increases platelet counts in healthy subjects. Eur J Cancer 2005; Suppl. 3 (2): 420
108. Xiao S, Renshaw M, Springhorn JP, et al. Therapeutic c-Mpl agonist antibodies accelerate platelet recovery in myelosuppressed mice. Blood 2003; 102: 774
109. Duffy KJ, Darcy MG, Delorme E, et al. Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytoopoiesis. J Med Chem 2001; 44 (22): 3730-45
110. Drayer AL, Olthof SG, Vellenga E. Mammalian target of rapamycin is required for thrombopoietin-induced proliferation of megakaryocyte progenitors. Stem Cells 2006; 24 (1): 105-14